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Abstract
Interstitial pneumonia with autoimmune features (IPAF) is a term to describe individuals with both interstitial lung disease (ILD) 
and combinations of other clinical, serologic, and/or pulmonary morphologic features, which presumably originate from an un-
derlying systemic autoimmune condition, but do not meet current rheumatologic criteria for a defined connective tissue disease 
(CTD). Predominantly, interstitial pneumonia arises in the course of an established CTD, but it is not so rare for the ILD to be 
the first, and possibly the one and only manifestation of a latent CTD. Lymphocytic Interstitial Pneumonia (LIP) is an uncommon 
disease, characterized by infiltration of the interstitium and alveolar spaces of the lung by lymphocytes, plasma cells and other 
lymphoreticular elements. The cause of LIP is still unknown but it could be also a manifestation of CTD. Clinically, it is highly 
variable, from spontaneous resolution to progressive respiratory failure and death despite glucocorticoid treatment. Since there 
are no recent standards for the management of LIP, the disease is treated empirically. 
We report a case of a HIV-negative 54-year-old woman, who was suspected of LIP according to clinical features and radiological 
findings. Positive laboratory results were highly suggestive of underlying autoimmune process, but did not fulfil the criteria of 
any particular CTD. Because of severe general condition of the patient, immunosuppressive treatment was started immediately, 
without further invasive diagnostics including lung biopsy, which is required for a definitive diagnosis. We present two-year 
observation of the patient with all our doubts concerning clinical proceedings. 
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Introduction
Interstitial pneumonia with autoimmune 
features (IPAF) is a  term given to characterize 
a heterogeneous group of patients with idiopathic 
interstitial pneumonia (IIP) who have a clinical 
flavour of underlying connective tissue disease 
(CTD) but do not meet the current American Col-
lege of Rheumatology criteria for it. The features 
from three domains are crucial for establishing 
diagnosis of IPAF: a clinical domain consisting 
of specific extra-thoracic features, a  serologic 
domain including specific autoantibodies, and 
a morphologic domain comprising specific chest 
imaging, histopathologic or pulmonary physiolo-
gic features. Interstitial pneumonia is one of the 
most common and known clinical manifestations 
of CTD. It can take different forms, including 
lymphocytic interstitial pneumonia (LIP). LIP is 
an uncommon disease that is histopathologically 
characterized by infiltration of the interstitium 
and alveolar spaces of the lung by lymphocytes, 
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plasma cells, and histiocytes [1]. LIP’s association 
with several autoimmune disorders including 
Sjögrens syndrome, systemic lupus erythematous 
(SLE), rheumatoid arthritis [2] and pernicious 
anaemia is well known. In general, changes 
characteristic of LIP have been reported in the 
course of viral infection, especially caused by 
HIV and EBV [3]. However, some of the cases 
remain idiopathic, when all systemic diseases are 
excluded and classified as IIP (idiopathic inter-
stitial pneumonia) [4]. Data concerning mortality 
and morbidity of the LIP are underestimated and 
inaccurate due to the lack of reported follow-up 
and rarity of the disease. Because of non-specific 
symptoms (non-productive cough, dyspnoea, 
crackles) and radiological changes (ground-glass 
appearance, bibasilar interstitial marking, honey-
combing, development of fibrosis, bronchiectasis, 
bullae or cystic changes), open lung biopsy sho-
uld be considered to verify the diagnosis and/or 
exclude other possible causes [3]. Differential 
diagnosis includes: pseudolymphoma, lympho-
matoid granulomatosis, follicular bronchiolitis, 
primary pulmonary lymphoma, bronchocentric 
granulomatosis, IgG4-related disease, hyper-
sensitivity pneumonitis (e.g, characterized by 
the non-specific interstitial pneumonia [NSIP] 
pattern) and pneumonia caused by Pneumocystis 
jirovecii, cytomegalovirus and mycobacteria in 
HIV-infected patients [5]. 
Due to the rarity of the disease and variety 
of possible aetiology, data regarding LIP treat-
ment commonly come from case series’ reports 
and therefore are still uncompleted. No treating 
standards have been established.
We present a case of a 54-year-old patient 
suspected of LIP, most likely secondary to con-
nective tissue disease (IPAF). The suspicion was 
based on clinical presentation, radiological fin-
dings and some laboratory abnormalities. 
Case report
A fifty-four-year-old woman was admitted 
in September 2013 to the Pulmonology Depart-
ment due to increasing rest dyspnoea and dry 
cough. First symptoms of respiratory distress 
on exertion occurred in January 2013. At that 
time the patient was diagnosed with interstitial 
pulmonary changes of unknown aetiology and 
secondary respiratory failure. Afterwards she 
has been given several courses of antibiotics due 
to the exacerbation in the course of the disease 
of infection origin. She was a  former smoker 
(30 pack-years). In her past medical history she 
reported pain in both hip-joints, which started 
in 1996. At first it was treated with NSAIDs by 
the GP with no rheumatological consultation. In 
2000 hip replacement was performed, no symp-
toms afterwards. Furthermore, 11 years ago she 
had thyreoidectomy due to goitrous thyroiditis. 
Neither other significant medical history, nor 
exposure to irritants, was reported. Her family 
and occupational history were unremarkable. 
When referred to the Pulmonology Department, 
she was in severe general condition, afebrile, 
with tachypnoe 30/min, heart beat 91/min, blood 
pressure 90/60mm Hg and saturation 71.6%. On 
the examination, central cyanosis was observed, 
when sitting, she tended to lean forward, she had 
clubbed fingers, dry tongue. No skin lesions were 
found. There were crackles in both lung fields 
on auscultation, heart rhythm was normal with 
no pathological sounds. No lymphoadenopathy 
was observed. The abdomen and extremities were 
unremarkable. 
The results of laboratory studies were as 
follows: complete cell count, liver function, re-
nal function, brain natriuretic peptide, TSH, the 
blood urea nitrogen, electrolyte test results and 
urine analysis were all within normal levels. The 
arterial blood gas revealed respiratory failure type 
1: pH 7,503; pCO2: 36.4 mm Hg; pO2:34.1 mm 
Hg; HCO2: 27.4 mmol/L; sat: 71.6%. Coagulation 
results showed elevated level of D-dimers up to 
1932 ng/mL. C-reactive protein was elevated to 
42.50 mg/L. The total protein was normal (74.5 
g/L), whereas the albumin level decreased to 
26.6 g/L and gamma-globulin increased to 25.0 
g/L. HIV antibody was negative. The rheumatoid 
factor was positive, but the results of anti-CCP 
antibodies were negative. The antinuclear antibo-
dy was over 1:10,000 with no anti-SSA, anti-SSB, 
anti-nRNP, anti-Sm, anti-Jo1 antibodies. However, 
anti-PM-Scl, anti-dsDNA, anti-nucleosoms, an-
ti-histons antibodies were found. No laboratory 
tests concerning lupus anticoagulant, anticar-
diolipin antibodies nor LE cells were performed. 
The body plethysmography showed a  low 
total lung capacity [TLC 65.9%]. The patient was 
not able to perform other pulmonary function 
tests (spirometry, diffusing capacity for carbon 
monoxide) due to severe rest dyspnoea.
On the echocardiography examination, left 
ventricle relaxation was decreased and pulmo-
nary hypertension with right ventricular systolic 
pressure (RVSP) of 60 mm Hg was found. High-re-
solution CT showed massive interstitial changes 
in both lung areas, diffuse ground-glass opacities, 
cysts up to 3 cm mostly located in the lower lobes 
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Figure 1. Radiological changes seen in HRCT in September 2013 (thanks to the Radiology Ward of SKPP UM in Poznań)
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Figure 2. Radiological changes seen in HRCT in the follow-up in July 2014 (thanks to the Radiology Ward of SKPP UM in Poznań)
of both lungs. All these radiological findings are 
very suggestive of LIP (Fig. 1).
According to rheumatological consultation, 
capillaroscopy and Schirmer’s test were perfor-
med and no abnormalities were observed.
Because of severe general condition of the 
patient, bad results of the pulmonary function te-
sts, coexisting respiratory failure and pulmonary 
hypertension, she was disqualified from further 
diagnostics including bronchoscopy with BAL 
and invasive procedures (VAT, transbronchial 
lung biopsy). The patient was diagnosed with the 
suspicion of LIP based on symptoms and typical 
radiological changes in the lung fields. Even 
though the connective tissue origin of the LIP in 
the described patient was highly suspected, in 
rheumatological opinion, the results presented 
above were insufficient to diagnose any particular 
disease. The anti-inflammatory treatment was 
started in hospital using systemic corticosteroids 
(500 mg of metyloprednisolone in pulses for 3 
days) and continued initially with 40 mg of pred-
nisone a day with gradual reduction of the dose at 
home. Because of coexisting chronic respiratory 
failure, the patient was advised to undergo the 
oxygen therapy (1.5 l/min as needed). 
After 10 months of taking systemic glucocor-
ticosteroids (GCs) with the minimal dose of 25 
mg prednisone, the patient reported pathological 
spine fracture. Then, she was admitted again to 
the Pulmonology Department for the assessment 
of the course of disease. On the follow-up exami-
nation, significant improvement with reduction 
of interstitial changes on the chest CT (Fig. 2) and 
RVSP in echocardiography (to 33 mm Hg) was ob-
served. What is more – the patient’s clinical status 
was good enough to perform all pulmonary tests 
including spirometry, body plethysmography and 
DLCO measurements. Forced vital capacity (FVC) 
and TLC results were within normal range, but 
DLCO suggested severe diffusion disorder (21.6% 
of predictive value). Apart from advantages, the 
immunosuppressive treatment caused some side 
effects such as the aforementioned spine fracture 
but also problems with vision, significant abdo-
minal obesity and vessels fragility. All of them 
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markedly reduced the patient’s quality of life. 
Then, the therapy with azathioprine was initiated, 
so as to decrease the dosage of GCs. Ultimately, 
the dose of methyloprednisolone was reduced to 
4 mg daily and administration of azathioprine 
100 mg a day was continued. 
Discussion
In 2015, ERS/ATS published a statement in 
which the necessity of introducing concept of 
IPAF was underlined. IPAF is recommended for 
all clinical situations, when the interstitial chan-
ges in the lungs are followed by autoantibodies’ 
positive tests with no particular CTD. However, 
there are still many doubts concerning the matter, 
as the classification is available for a very short 
period of time. Several months ago another article 
referring to IPAF was published revealing queries 
about the terminology. The authors agreed with 
Fischer et al. [2] that the term ‘IPAF’ is necessary, 
but emphasized that the terminology is still not 
validated and there is still a huge group of patients 
that do not meet all criteria for CTD or IPAF [3]. To 
fulfil the criteria for IPAF, the patient must have 
radiological features and/or lung biopsy. If the 
patient fails to meet criteria for a specific CTD, 
and IIP are excluded, he must have at least one 
characteristic from at least two out of: clinical, 
serological and morphological domains. 
In general, due to ATS/ERS classification, LIP 
develops mainly secondarily to viral infection 
[6], it may be of connective tissue disease origin, 
but several studies still suggest there may be 
cases of idiopathic LIP [4, 6]. This fact has been 
confirmed in the last International Multidiscipli-
nary Classification of the Idiopathic Interstitial 
Pneumonias (IIPs), where idiopathic LIP was 
included in the category of rare IIPs [7]. In the 
presented patient, HIV infection was excluded at 
the beginning, there were no symptoms suggestive 
of EBV infection or immunodeficiency. However, 
her interstitial lung disease was associated with 
autoantibody production. The patient did not 
meet the criteria of a particular connective tissue 
disease, but HRCT radiological pattern suggestive 
of LIP and serological features fulfilled the criteria 
of IPAF [2]. 
According to the 2002 ATS/ERS classifica-
tion of IIPs, diagnosis of LIP was possible when 
clinical, imaging and histopathologic criteria 
occurred, so thoracoscopic or open-lung biopsy 
specimens are required [8]. The question is — 
whether the radiographic pattern and symptoms 
in HIV-positive children are sufficient to diagnose 
LIP without invasive procedures [9], and how 
to classify adult patients that meet most of the 
criteria apart from pathological findings? How 
to diagnose patients who are disqualified from 
further invasive procedures because of severe 
clinical condition? Similar dilemma was highli-
ghted in the newest classification of IIPs of 2013 in 
which the historical gold standard of histological 
diagnosis was replaced by a “dynamic integrated 
approach” using multidisciplinary discussion. 
The multidisciplinary approach does not lessen 
the importance of lung biopsy in the diagnosis of 
IIPs. It defines the settings where biopsy is more 
informative than HRCT and those where biopsy 
is not needed [7]. In this document, LIP is not 
listed as an example when invasive diagnosis 
is not required, but it did not give the answer 
to doubts what to do in the case of suspicion of 
disease and disqualification from invasive proce-
dures. Regarding the above, the typical clinical 
presentation and CT images without the results 
of the biopsy were sufficient just to suspect LIP 
in the described patient without establishing 
a final diagnosis.
Due to the rarity of the disease, the data con-
cerning morbidity, mortality and treatment are 
uncompleted. Controlled clinical trials have not 
been reported for LIP. Data related to therapeutic 
options are available through case reports. The 
treatment of adults with LIP differs depending on 
the severity of the patient’s symptoms, presented 
impairments in pulmonary function tests, and the 
presence or absence of a coexistent disease. So 
far no specific guidelines have been established. 
In general, most data originate from patients with 
autoimmune disease in whom systemic glucocor-
ticosteroids have been administered. The opti-
mal dose and duration of such therapy are also 
uncertain. The primary objective is to obtain the 
maximum effect with the minimum dose. 
It is suggested that the initial dose of pred-
nisone 0.75 should amount to 1mg/kg given once 
daily (max. 100 mg). The dose is continued for 
8 to 12 weeks, then slowly reduced to the mini-
mal one. The therapeutic effects are controlled 
by patient’s symptoms, radiological findings 
on HRCT and pulmonary function tests (FVC, 
TLC, DLCO). As systemic steroid therapy does 
not meet expected effects in all patients, the 
next step is to enclose immune suppressants 
like azathioprine or cyclosporine A. That seems 
to be the most successful therapy [6, 10, 11], 
however, there is a  report that has described 
good response to cyclosporine A after no impro-
vement with steroids [11]. Furthermore, impro-
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vement in LIP associated with common variable 
immunodeficiency syndrome (CVID) treated 
with immunoglobulin without steroids and 
immune suppressants has also been published 
[12]. In 2013, a good response to Mycopheno-
late Mofetil was reported among patients with 
idiopathic LIP alone, as well as both LIP and 
connective tissue disorder [13, 14]. In Poland, 
Mycophenolate Mofetil is not registered for 
the treatment of LIP. In this case, no particular 
connective tissue disease has been diagnosed, 
probably due to permanent steroid therapy. Mo-
reover, chronic treatment with oral steroids (25 
mg of prednisone) has caused many side effects 
such as osteoporosis, obesity, vessels fragility, 
cataract. On the other hand, lower doses of oral 
steroids have increased symptoms and caused 
deterioration of general condition. Thus, our 
patient has been given azathioprine, in order 
to minimize the dose of systemic steroids. In 
24-month-long follow-up she seems to improve 
and her respiratory symptoms are stable. 
Conclusion
In general, LIP is still underdiagnosed and 
underestimated due to its rarity. Many data 
concerning pathogenesis, clinical, radiological 
features and treatment are inexact. As there are 
so many doubts and uncertainty, the question 
remains if those cases diagnosed previously as 
idiopathic interstitial pneumonias when tested 
positively for any autoantibodies, should be 
treated as IPAF? The Update of the International 
Multidisciplinary Classification of the Idiopathic 
Interstitial Pneumonias of 2013 and other recent 
publications concerning IIP may be helpful for 
doctors taking care of such group of the patients 
regarding diagnostic doubts. 
What kind of treatment should be applied so 
as to extend patients’ life expectancy and improve 
their quality of life? Since there is no standard 
therapy established, every information on the 
issue is very valuable. Additional clinical trials 
and studies are needed. Yet, the most important is 
to weigh the risk of side effects against potential 
benefits, and ensure the patient the best quality 
of life.
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